This article is more than 5 years old. Information may no longer be current.
Deep sclerectomy with MMC lowers IOP in uveitic glaucoma
Eur J Ophthalmol. 2011;21(6):708-714.
Click Here to Manage Email Alerts
Use of mitomycin C with deep sclerectomy lowered IOP in cases of uveitic glaucoma, a study found. In addition, the complication rate was low.
Researchers reported on the outcomes of deep sclerectomy with MMC in a retrospective cases series involving 26 eyes of 26 patients with uveitic glaucoma. All eyes had elevated IOP secondary to uveitis. The researcher applied MMC 0.2 mg/mL to 0.4 mg/mL subconjunctivally for 2 to 3 minutes before scleral flap dissection.
Follow-up ranged from 12 months to 83 months, with a mean of 46.5 months.
Results showed that 15 eyes had previous intraocular surgery; preoperative IOP was about 33 mm Hg. After surgery, IOP was about 13 mm Hg at 1 year, 13 mm Hg at 2 years and 14 mm Hg at 3 years.
Six eyes required needle revision, and three patients needed additional glaucoma surgery, according to the study.
Use of glaucoma medications decreased from about 3.3 to 0.3 at last follow-up. Four eyes required medications to control IOP. Uveitis recurrence occurred in 11 eyes, but there was no loss in IOP control.
Three eyes experienced intraoperative perforation of the trabeculo-Descemet's membrane, and four eyes experienced late iris entrapment in perforation or goniopuncture.